Dr Stuart Carr provides his perspective on the latest understanding of the aetiology, pathophysiology and clinical manifestations of EoE.1/3 Next Interview
Dr Mário Vieira provides his perspective on the diagnosis and management of paediatric patients with EoE, based on an example patient case.2/3 Next Interview
Prof. Arjan Bredenoord provides his perspective on the diagnosis and management of adult patients with EoE, based on an example patient case.3/3 Take CE/CME Test
Learning Objectives & Overview
In this activity, international experts discuss the latest understanding of eosinophilic oesophagitis (EoE) pathophysiology, how to differentiate EoE from gastro-oesophageal reflux disease, and current and future treatment and monitoring options for patients with EoE.
This activity is jointly provided by USF Health and touchIME. read more
This activity has been designed to meet the educational needs of adult and paediatric gastroenterologists, adult and paediatric allergists/immunologists, paediatricians, advanced nurse practitioners, physician assistants and practice nurses involved in the management of patients with eosinophilic oesophagitis.
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Dr Stuart Carr discloses: Advisory board/panel fees from Sanofi/Genzyme. Consultancy fees from Aralez Canada. Speaker’s bureau fees from Sanofi/Genzyme.
Dr Mário Vieira discloses: Advisory board/panel fees from Danone Nutricia. Speaker’s bureau fees from Aché Laboratories, Danone Nutricia, Nestlé Nutrition.
Prof. Arjan Bredenoord discloses: Advisory board/panel fees from Alimentiv, Arena Pharmaceuticals Inc., AstraZeneca, Calypso Biotech, Dr. Falk Pharma, EsoCap, Laborie, Medtronic, Reckitt, Regeneron Pharmaceuticals Inc. and Sanofi. Consultancy fees from Alimentiv, Arena Pharmaceuticals Inc., AstraZeneca, Calypso Biotech, Dr. Falk Pharma, EsoCap, Laborie, Medtronic, Reckitt, Regeneron Pharmaceuticals Inc. and Sanofi. Grants/research support from Nutricia and Thelial; Bayer, Dr. Falk Pharma, Gossamer Bio, Norgine and SST (relationships terminated). Speaker’s bureau fees from AstraZeneca, Dr. Falk Pharma, Laborie, Medtronic, Regeneron Pharmaceuticals Inc. and Sanofi.
John Jacobs MD has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Directors
Anne Nunn and Kathy Day have no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact firstname.lastname@example.org.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 18 August 2022. Date credits expire: 18 August 2023.
If you have any questions regarding credit please contact email@example.com.
After watching this activity, participants should be better able to:
- Describe the complex pathophysiology of EoE and how this manifests as clinical symptoms throughout life
- Distinguish eosinophilic oesophagitis as a progressive disease that is distinct from GORD
- Summarize the clinical evidence supporting the use of emerging biologic treatments for EoE